ALPHA TAU MEDICAL LTD (DRTS) Forecast, Price Target & Analyst Ratings
NASDAQ:DRTS • IL0011839383
6.84 USD
+0.13 (+1.94%)
At close: Mar 10, 2026
6.84 USD
0 (0%)
Pre-Market: 3/11/2026, 5:05:58 AM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for ALPHA TAU MEDICAL LTD (DRTS).
Forecast Snapshot
Consensus Price Target
$8.42
+ 23.03% Upside
Next Earnings Forecast
Release DateN/A
PeriodQ1 / 2026
EPS Estimate-$0.12
Revenue Estimate64.597K
ChartMill Buy Consensus
86.00%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$8.42
Upside
+ 23.03%
From current price of $6.84 to mean target of $8.42, Based on 10 analyst forecasts
Low
$5.05
Median
$8.16
High
$12.60
Price Target Revisions
1 Month
0.00%
3 Months
-2.94%
Price Target Summary
10 Wall Street analysts provided a forecast for the next 12 months for DRTS. The average price target is 8.41 USD. This implies a price increase of 23.03% is expected in the next year compared to the current price of 6.84.
The average price target has been revised downward by 2.94% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
86.00%
DRTS was analyzed by 10 analysts. The buy percentage consensus is at 86. So analysts seem to be very confident about DRTS.
In the previous month the buy percentage consensus was at a similar level.
DRTS was analyzed by 10 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2026-03-04 | Piper Sandler | Downgrade | Overweight -> Neutral |
| 2026-02-24 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-12-10 | Citigroup | Maintains | Buy -> Buy |
| 2025-11-24 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-10-22 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-09-03 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-04-29 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-17 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-22 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-23 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-11 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-20 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-15 | Piper Sandler | Reiterate | Overweight -> Overweight |
| 2024-06-26 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-22 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-16 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-03-12 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-03-08 | Piper Sandler | Reiterate | Overweight -> Overweight |
| 2023-12-15 | Citigroup | Initiate | Buy |
| 2023-11-20 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-11-17 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2023-09-20 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-08-29 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2023-08-29 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
Next Earnings Forecast Details
Next Earnings Details
Release DateN/A
PeriodQ1 / 2026
EPS Estimate-$0.12
Revenue Estimate64.597K
Revenue Q2QN/A
EPS Q2Q0.83%
Number of Analysts5
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
0.00%
EPS (3 Months)
0.00%
Next Earnings Summary
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A 1,055.39% | N/A 333.78% | N/A 113.40% | N/A 52.50% | |||||||
| EBITDA YoY % growth | -7.94M | -9.15M -15.24% | -13.01M -42.19% | -31.16M -139.51% | -34.606M -11.06% | -34.94M -0.97% | N/A -14.99% | N/A -7.96% | N/A 19.66% | N/A | N/A | N/A | |
| EBIT YoY % growth | -8.01M | -9.24M -15.36% | -13.79M -49.24% | -32.14M -133.07% | -35.68M -11.01% | -36.042M -1.01% | N/A -14.40% | N/A -7.81% | N/A 18.79% | N/A 86.13% | N/A 1,089.82% | N/A 106.02% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | -0.66 -148.87% | -0.42 36.36% | -0.45 -7.14% | -0.47 -4.44% | N/A -4.28% | N/A 23.48% | N/A 102.72% | N/A 5,700.00% | N/A 100.00% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.12 0.83% | -0.12 5.85% | -0.12 12.57% | -0.12 -48.75% | -0.11 5.72% | -0.10 20.83% | -0.08 37.50% | -0.06 48.57% |
| Revenue Q2Q % growth | 64.597K | 153K | 448.8K | 873.803K | 2.076M 3,113.79% | 4.085M 2,569.93% | 7.507M 1,572.68% | 10.557M 1,108.17% |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -11.533M -23.90% | -10.827M -12.22% | -11.439M -6.61% | -11.079M -1.15% | -11.016M 4.48% | -9.415M 13.05% | -7.14M 37.58% | -3.59M 67.59% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
26.45%
EPS Next 5 Year
35.20%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
1.57%
EBIT Next 5 Year
N/A
ALPHA TAU MEDICAL LTD / DRTS Forecast FAQ
What is the price target for DRTS stock?
10 analysts have analysed DRTS and the average price target is 8.41 USD. This implies a price increase of 23.03% is expected in the next year compared to the current price of 6.84.
What are the consensus estimates for DRTS stock next earnings?
The consensus EPS estimate for the next earnings of ALPHA TAU MEDICAL LTD (DRTS) is -0.12 USD and the consensus revenue estimate is 64.60K USD.